Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation of $0 in Q2 FY2026

Q2 FY2026 stock-based compensation was $0.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 stock-based compensation of $0 is the 9th largest of the 10 companies compared; the peer median is $11.32M.
  • Stock-based compensation amounts to 0.0% of revenue for ATTO, versus a peer median of 80.8%.
ATTO Competitors Peer median
Stock-Based Compensation for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M +24.3%+9.7%17.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$36.4M -7.4%+94.0%492.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$23.96M +203.5%+10.1%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
ZURAZura Bio LimitedLTM Mar 2026$11.32M -37.2%+233.0%—
ORKAOruka Therapeutics, Inc.LTM Sep 2026$9.13M -54.6%——
QTTBQ32 Bio Inc.LTM Mar 2026$3.99M -24.8%+61.9%7.4%
CNTBConnect Biopharma Holdings LimitedFY2025$3.73M -44.6%+54.6%5821.9%
ATTOAttovia Therapeutics, Inc.FY2025$0 ——0.0%
EVMNEvommune, Inc.LTM Mar 2026$0 ——0.0%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ATTO) $11.32M-16.1%+54.6%80.8%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.